Hohl Benjamin

CHIEF FINANCIAL OFFICEREnliven Therapeutics, Inc. (ELVN) · full profile →Form 4 · filed Aug 19, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$353K
Net Open-Market Flow
-$353K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 17, 2026Sell(S)5K$58.35$270K41K
Aug 17, 2026Sell(S)1K$59.35$82K40K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001882764-26-000007) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.